According to Moderna CEO Stephane Bancel, it’s logical to believe that the pandemic is nearing its end.
He stated on Wednesday that an 80% possibility exists that when omicron or the SarsCov-2 virus evolves, we will see fewer and fewer virulent viruses. He also mentioned a 20 percent possibility in which a new mutation emerges that is more pathogenic than omicron.
The World Health Organization states that 15.47 million new cases were reported worldwide in the last seven days, with 73,162 deaths.
According to some research, while the omicron version looks to be more contagious, it does not make individuals sick as much as the delta variety. Health officials have reportedly stated that the threat posed by omicron may be diminishing.
However, the World Health Organization’s director-general, Dr. Tedros Adhanom Ghebreyesus, stressed in January that assuming the pandemic is nearing its finale is risky. In fact, he claims it’s far from over, warning that as omicron spreads fast over the world, other variations will inevitably develop.
Moderna said in January that it has begun a clinical trial to assess the effectiveness and safety of a booster dose that targets the omicron variety.
Moderna, on the other hand, has declared plans to extend its footprint in Asia. “The reason we want to expand in Asia is the importance of that region,” he explains.
Bancel described Asia’s economic boom as extremely exciting, adding that the business plans to expand in Malaysia, Taiwan, Singapore, and Hong Kong.
Moderna mentioned in a statement that the company is expanding to continue to grow the production and delivery of its COVID-19 vaccine as well as future mRNA vaccines and medicines.
In Hong Kong, where Covid instances have lately increased, Moderna’s messenger RNA immunization is presently unavailable. The corporation is presently negotiating with authorities to have it authorized, according to Bancel.
